

Table 1. Demographic and Clinical Characteristics

	Belgium LRx			France LRx		Germany LRx				Netherlands LRx			Sweden		
	exBID N=80	LIXI N=20	LIRA N=666	exBID N=1,884	LIRA N=8,606	exQW N=1,035	exBID N=2,261	LIXI N=1,731	LIRA N=6,916	exQW N=122	exBID N=44	LIRA N=1,324	exQW N=342	exBID N=70	LIRA N=3,443
Age at Index (%)^a															
18-39	2.6	5.0	2.9	0.9	1.9	5.5	5.4	4.7	5.3	4.9	2.3	5.6	3.5	s	4.1
40-49	12.5	10.0	12.5	6.7	10.2	17.3	15.9	16.6	16.2	18.0	11.4	19.3	14.0	s	15.2
50-64	46.3	45.0	51.2	47.6	51.0	48.9	52.5	49.2	52.3	41.8	59.1	47.4	52.3	48.6	48.3
65+	38.8	40.0	33.0	44.8	36.9	28.4	26.3	29.5	26.2	35.3	27.3	27.7	30.1	40.0	32.4
Mean				62.9	60.9	58.1	57.8	58.2	57.7	58.7	59.8	57.1	59.1	60.9	58.8
SD				9.6	9.8	11.5	10.9	10.9	10.9	10.6	9.9	10.8	10.2	10.9	10.5
Median				63	61	58	58	59	58	60	60	58	60	62	60
Female (%)^b	53.8	55.0	47.3			54.8	53.8	52.6	53.0	45.1	47.7	55.1	59.9	61.4	59.2
Follow-up (months)															
Mean	26.6	20.0	25.9	30.7	30.6	25.8	26.1	25.3	25.9	26.9	25.5	26.6	18.3	17.7	17.7
SD	4.1	2.4	4.5	2.2	2.2	5.2	5.0	3.8	4.8	4.8	5.0	4.8	3.4	3.2	3.3
Median	27	21	26	31	31	26	27	26	26	28	26	27	19	18	18
Number of antihyperglycemic therapy classes used in the 180-day Pre-Index Period															
Mean	1.7	3.0	2.0	2.1	2.1	1.6	2.0	2.3	1.7	2.3	2.0	2.3	2.1	2.0	2.0
SD	1.2	0.9	1.0	0.8	0.8	1.0	1.1	1.0	1.1	0.8	1.0	0.9	0.9	1.0	0.9
Median	2	3	2	2	2	1	2	2	2	2	2	2	2	2	2
Frequent (>10%) antihyperglycemic therapy classes used in the 180-day Pre-Index Period^c															
Fast-acting insulin	6.2	20.0	2.7	4.4	6.0	12.1	25.5	23.7	15.9	5.7	18.1	18.0	19.2	27.1	22.6
Intermediate-acting insulin	1.2	25.0	2.5	1.4	1.1	6.2	14.3	10.2	6.2	3.2	2.2	3.1	21.6	28.5	22.9
Intermediate/fast-acting insulin	2.5	0.0	2.1	1.3	2.3	1.1	3.5	2.8	2.0	3.2	2.2	5.5	8.4	22.8	11.3
Long-acting insulin	8.7	55.0	4.0	22.2	25.0	13.7	26.2	39.2	19.9	10.6	29.5	26.2	14.6	20.0	21.0
Biguanide	61.2	85.0	79.4	87.3	86.9	54.0	64.7	63.3	64.5	88.5	70.4	84.6	82.1	74.2	79.8
DPP-IV	22.5	35.0	27.9	4.1	2.8	17.2	13.4	19.2	13.8	32.7	6.8	18.1	28.6	s	18.1
DPP-IV/Biguanide	1.2	0.0	3.7	4.1	3.6	30.0	22.8	35.6	21.9	7.3	0.0	3.1	3.2	s	1.7
Glinide	22.5	15.0	13.2	14.5	14.0	5.2	4.7	6.5	5.0	0.8	0.0	0.0	5.5	s	3.8
Sulfonylurea	43.7	60.0	64.8	64.5	58.2	17.6	17.3	16.9	16.9	74.5	56.8	62.0	27.1	14.2	21.4

<i>None</i>	23.7	0.0	11.2	0.1	0.3	9.3	8.5	2.3	9.6	0.0	6.8	3.0	<i>s</i>	<i>s</i>	1.6
Number of concomitant antihyperglycemic therapy classes used on the Index Date^d															
Mean	1.6	2.0	1.6	2.0	1.9	1.0	1.2	1.2	1.1	1.6	1.5	1.4	1.2	1.4	1.26
SD	0.8	1.0	0.7	0.7	0.8	0.8	0.8	0.9	0.8	0.8	0.7	0.8	0.9	0.9	0.9
Median	2	2	2	2	2	1	1	1	1	2	2	1	1	1	1
Frequent (>10%) concomitant antihyperglycemic therapy classes used on the Index Date^{c,d}															
Fast-acting insulin	5.0	5.0	0.9	2.8	4.5	7.2	10.5	10.9	7.0	2.4	4.5	3.9	9.3	14.2	13.1
Intermediate-acting insulin	0.0	15.0	1.0	1.0	0.9	1.9	7.6	5.4	2.2	0.0	2.2	0.3	13.7	20.0	15.0
Long-acting insulin	7.5	50.0	1.3	18.3	21.2	7.5	16.1	24.3	12.1	4.9	6.8	6.1	8.7	15.7	16.4
Biguanide	76.2	70.0	80.0	83.9	82.7	56.0	64.4	54.5	64.6	77.0	79.5	72.3	53.5	54.2	57.4
Glinide	23.7	15.0	9.0	12.6	12.5	3.1	2.6	3.3	3.2	0.0	0.0	0.0	3.2	<i>s</i>	2.1
Sulfonylurea	46.2	45.0	66.2	59.2	53.0	8.5	8.3	5.3	8.5	62.2	56.8	53.3	16.6	<i>s</i>	11.0
<i>None</i>	6.2	10.0	7.6	3.7	4.2	24.5	18.0	23.1	20.0	11.4	6.8	13.2	21.6	15.7	18.0

^aContinuous age unavailable in Belgium LRx; ^bOut of non-missing gender in Germany LRx; Gender unavailable in France LRx; ^cNot mutually exclusive; ^dConcomitant = 1) time between therapy class prescriptions in pre- and post-index of 120 days or less, with overlap on index or 2) with prescription on the index date.

s = Data suppressed in Sweden due to patient count less than 10 in compliance with Swedish privacy legislation. exBID=exenatide twice-daily; exQW=exenatide once-weekly; LIXI=lixisenatide; LIRA=liraglutide